{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,26]],"date-time":"2026-10-26T18:03:39Z","timestamp":1793037819421,"version":"4.5.0"},"reference-count":105,"publisher":"Springer Science and Business Media LLC","issue":"4","license":[{"start":{"date-parts":[[2021,7,8]],"date-time":"2021-07-08T00:00:00Z","timestamp":1625702400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2021,7,8]],"date-time":"2021-07-08T00:00:00Z","timestamp":1625702400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/501100001659","name":"Deutsche Forschungsgemeinschaft","doi-asserted-by":"publisher","award":["SFB841"],"award-info":[{"award-number":["SFB841"]}],"id":[{"id":"10.13039\/501100001659","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100006006","name":"ICIN Netherlands Heart Institute","doi-asserted-by":"publisher","award":["DCVA grant 2018-27"],"award-info":[{"award-number":["DCVA grant 2018-27"]}],"id":[{"id":"10.13039\/501100006006","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Semin Immunopathol"],"published-print":{"date-parts":[[2021,8]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>Bile acids and their signaling pathways are increasingly recognized as potential therapeutic targets for cholestatic and metabolic liver diseases. This review summarizes new insights in bile acid physiology, focusing on regulatory roles of bile acids in the control of immune regulation and on effects of pharmacological modulators of bile acid signaling pathways in human liver disease. Recent mouse studies have highlighted the importance of the interactions between bile acids and gut microbiome. Interfering with microbiome composition may be beneficial for cholestatic and metabolic liver diseases by modulating formation of secondary bile acids, as different bile acid species have different signaling functions. Bile acid receptors such as FXR, VDR, and TGR5 are expressed in a variety of cells involved in innate as well as adaptive immunity, and specific microbial bile acid metabolites positively modulate immune responses of the host. Identification of Cyp2c70 as the enzyme responsible for the generation of hydrophilic mouse\/rat-specific muricholic acids has allowed the generation of murine models with a human-like bile acid composition. These novel mouse models will aid to accelerate translational research on the (patho)physiological roles of bile acids in human liver diseases .<\/jats:p>","DOI":"10.1007\/s00281-021-00869-6","type":"journal-article","created":{"date-parts":[[2021,7,8]],"date-time":"2021-07-08T03:03:13Z","timestamp":1625713393000},"page":"577-590","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":109,"title":["Role of bile acids in inflammatory liver diseases"],"prefix":"10.1007","volume":"43","author":[{"given":"Ioannis","family":"Evangelakos","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5647-1034","authenticated-orcid":false,"given":"Joerg","family":"Heeren","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Esther","family":"Verkade","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2518-737X","authenticated-orcid":false,"given":"Folkert","family":"Kuipers","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2021,7,8]]},"reference":[{"key":"869_CR1","doi-asserted-by":"publisher","first-page":"137","DOI":"10.1146\/annurev.biochem.72.121801.161712","volume":"72","author":"DW Russell","year":"2003","unstructured":"Russell DW (2003) The enzymes, regulation, and genetics of bile acid synthesis. Annu Rev Biochem 72:137\u2013174","journal-title":"Annu Rev Biochem"},{"issue":"8","key":"869_CR2","doi-asserted-by":"publisher","first-page":"1553","DOI":"10.1194\/jlr.R049437","volume":"55","author":"AF Hofmann","year":"2014","unstructured":"Hofmann AF, Hagey LR (2014) Key discoveries in bile acid chemistry and biology and their clinical applications: history of the last eight decades. J Lipid Res 55(8):1553\u20131595","journal-title":"J Lipid Res"},{"issue":"2","key":"869_CR3","doi-asserted-by":"publisher","first-page":"151","DOI":"10.1016\/j.cmet.2013.07.009","volume":"18","author":"AK Groen","year":"2013","unstructured":"Groen AK, Kuipers F (2013) Bile acid look-alike controls life span in C. elegans. Cell Metab 18(2):151\u2013152","journal-title":"Cell Metab"},{"issue":"1","key":"869_CR4","doi-asserted-by":"publisher","first-page":"147","DOI":"10.1152\/physrev.00010.2008","volume":"89","author":"P Lefebvre","year":"2009","unstructured":"Lefebvre P, Cariou B, Lien F, Kuipers F, Staels B (2009) Role of bile acids and bile acid receptors in metabolic regulation. Physiol Rev 89(1):147\u2013191","journal-title":"Physiol Rev"},{"issue":"12","key":"869_CR5","doi-asserted-by":"publisher","first-page":"701","DOI":"10.1038\/s41574-019-0266-7","volume":"15","author":"TR Ahmad","year":"2019","unstructured":"Ahmad TR, Haeusler RA (2019) Bile acids in glucose metabolism and insulin signalling - mechanisms and research needs. Nat Rev Endocrinol 15(12):701\u2013712","journal-title":"Nat Rev Endocrinol"},{"key":"869_CR6","doi-asserted-by":"publisher","first-page":"175","DOI":"10.1146\/annurev-nutr-082018-124344","volume":"39","author":"JYL Chiang","year":"2019","unstructured":"Chiang JYL, Ferrell JM (2019) Bile acids as metabolic regulators and nutrient sensors. Annu Rev Nutr 39:175\u2013200","journal-title":"Annu Rev Nutr"},{"key":"869_CR7","doi-asserted-by":"publisher","first-page":"101094","DOI":"10.1016\/j.plipres.2021.101094","volume":"82","author":"S Fiorucci","year":"2021","unstructured":"Fiorucci S, Distrutti E, Carino A, Zampella A, Biagioli M (2021) Bile acids and their receptors in metabolic disorders. Prog Lipid Res 82:101094","journal-title":"Prog Lipid Res"},{"key":"869_CR8","doi-asserted-by":"publisher","first-page":"19","DOI":"10.1007\/164_2019_230","volume":"256","author":"V Keitel","year":"2019","unstructured":"Keitel V, Stindt J, Haussinger D (2019) Bile acid-activated receptors: GPBAR1 (TGR5) and other G protein-coupled receptors. Handb Exp Pharmacol 256:19\u201349","journal-title":"Handb Exp Pharmacol"},{"key":"869_CR9","doi-asserted-by":"publisher","first-page":"51","DOI":"10.1007\/164_2019_236","volume":"256","author":"DJ Shin","year":"2019","unstructured":"Shin DJ, Wang L (2019) Bile Acid-Activated Receptors: A Review on FXR and Other Nuclear Receptors. Handb Exp Pharmacol 256:51\u201372","journal-title":"Handb Exp Pharmacol"},{"issue":"6","key":"869_CR10","doi-asserted-by":"publisher","first-page":"166101","DOI":"10.1016\/j.bbadis.2021.166101","volume":"1867","author":"X Cai","year":"2021","unstructured":"Cai X, Young GM, Xie W (2021) The xenobiotic receptors PXR and CAR in liver physiology, an update, Biochimica et biophysica acta. Mol Basis Dis 1867(6):166101","journal-title":"Mol Basis Dis"},{"issue":"1","key":"869_CR11","doi-asserted-by":"publisher","first-page":"350","DOI":"10.1002\/hep.28709","volume":"65","author":"JP Arab","year":"2017","unstructured":"Arab JP, Karpen SJ, Dawson PA, Arrese M, Trauner M (2017) Bile acids and nonalcoholic fatty liver disease: Molecular insights and therapeutic perspectives. Hepatology 65(1):350\u2013362","journal-title":"Hepatology"},{"issue":"9","key":"869_CR12","doi-asserted-by":"publisher","first-page":"1332","DOI":"10.1002\/hep4.1518","volume":"4","author":"SB Roberts","year":"2020","unstructured":"Roberts SB, Ismail M, Kanagalingam G, Mason AL, Swain MG, Vincent C, Yoshida EM, Tsien C, Flemming JA, Janssen HLA, Hirschfield GM, Hansen BE, Gulamhusein AF (2020) D. Canadian Network for Autoimmune Liver, Real-world effectiveness of obeticholic acid in patients with primary biliary cholangitis. Hepatol Commun 4(9):1332\u20131345","journal-title":"Hepatol Commun"},{"issue":"13","key":"869_CR13","doi-asserted-by":"publisher","first-page":"1809","DOI":"10.1080\/14656566.2016.1218471","volume":"17","author":"AH Ali","year":"2016","unstructured":"Ali AH, Lindor KD (2016) Obeticholic acid for the treatment of primary biliary cholangitis. Expert Opin Pharmacother 17(13):1809\u20131815","journal-title":"Expert Opin Pharmacother"},{"issue":"11","key":"869_CR14","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0025006","volume":"6","author":"C Steiner","year":"2011","unstructured":"Steiner C, Othman A, Saely CH, Rein P, Drexel H, von Eckardstein A, Rentsch KM (2011) Bile acid metabolites in serum: intraindividual variation and associations with coronary heart disease, metabolic syndrome and diabetes mellitus. PLoS One 6(11):e25006","journal-title":"PLoS One"},{"issue":"1","key":"869_CR15","doi-asserted-by":"publisher","first-page":"108212","DOI":"10.1016\/j.celrep.2020.108212","volume":"33","author":"L Chen","year":"2020","unstructured":"Chen L, van den Munckhof ICL, Schraa K, Ter Horst R, Koehorst M, van Faassen M, van der Ley C, Doestzada M, Zhernakova DV, Kurilshikov A, Bloks VW, Groen AK, P. Human Functional Genomics, Riksen NP, Rutten JHW, Joosten LAB, Wijmenga C, Zhernakova A, Netea MG, Fu J, Kuipers F (2020) Genetic and microbial associations to plasma and fecal bile acids in obesity relate to plasma lipids and liver fat content. Cell Rep 33(1):108212","journal-title":"Cell Rep"},{"issue":"12","key":"869_CR16","doi-asserted-by":"publisher","first-page":"4184","DOI":"10.2337\/db13-0639","volume":"62","author":"RA Haeusler","year":"2013","unstructured":"Haeusler RA, Astiarraga B, Camastra S, Accili D, Ferrannini E (2013) Human insulin resistance is associated with increased plasma levels of 12alpha-hydroxylated bile acids. Diabetes 62(12):4184\u20134191","journal-title":"Diabetes"},{"issue":"3","key":"869_CR17","doi-asserted-by":"publisher","first-page":"194","DOI":"10.1097\/MOL.0000000000000508","volume":"29","author":"JF de Boer","year":"2018","unstructured":"de Boer JF, Bloks VW, Verkade E, Heiner-Fokkema MR, Kuipers F (2018) New insights in the multiple roles of bile acids and their signaling pathways in metabolic control. Curr Opin Lipidol 29(3):194\u2013202","journal-title":"Curr Opin Lipidol"},{"issue":"3","key":"869_CR18","doi-asserted-by":"publisher","first-page":"257","DOI":"10.4093\/dmj.2019.0043","volume":"43","author":"JM Ferrell","year":"2019","unstructured":"Ferrell JM, Chiang JYL (2019) Understanding bile acid signaling in diabetes: from pathophysiology to therapeutic targets. Diabetes Metab J 43(3):257\u2013272","journal-title":"Diabetes Metab J"},{"issue":"12","key":"869_CR19","doi-asserted-by":"publisher","first-page":"2130","DOI":"10.1194\/jlr.M071183","volume":"57","author":"S Takahashi","year":"2016","unstructured":"Takahashi S, Fukami T, Masuo Y, Brocker CN, Xie C, Krausz KW, Wolf CR, Henderson CJ, Gonzalez FJ (2016) Cyp2c70 is responsible for the species difference in bile acid metabolism between mice and humans. J Lipid Res 57(12):2130\u20132137","journal-title":"J Lipid Res"},{"issue":"4","key":"869_CR20","doi-asserted-by":"publisher","first-page":"1045","DOI":"10.1016\/j.jcmgh.2020.12.004","volume":"11","author":"JF de Boer","year":"2021","unstructured":"de Boer JF, de Vries HD, Palmiotti A, Li R, Doestzada M, Hoogerland JA, Fu J, La Rose AM, Westerterp M, Mulder NL, Hovingh MV, Koehorst M, Kloosterhuis NJ, Wolters JC, Bloks VW, Haas JT, Dombrowicz D, Staels B, van de Sluis B, Kuipers F (2021) Cholangiopathy and biliary fibrosis in Cyp2c70-deficient mice are fully reversed by ursodeoxycholic acid. Cell Mol Gastroenterol Hepatol 11(4):1045\u20131069","journal-title":"Cell Mol Gastroenterol Hepatol"},{"issue":"1","key":"869_CR21","doi-asserted-by":"publisher","first-page":"54","DOI":"10.1194\/jlr.RA119000395","volume":"61","author":"A Honda","year":"2020","unstructured":"Honda A, Miyazaki T, Iwamoto J, Hirayama T, Morishita Y, Monma T, Ueda H, Mizuno S, Sugiyama F, Takahashi S, Ikegami T (2020) Regulation of bile acid metabolism in mouse models with hydrophobic bile acid composition. J Lipid Res 61(1):54\u201369","journal-title":"J Lipid Res"},{"issue":"4","key":"869_CR22","doi-asserted-by":"publisher","first-page":"480","DOI":"10.1194\/jlr.RA119000307","volume":"61","author":"S Straniero","year":"2020","unstructured":"Straniero S, Laskar A, Savva C, Hardfeldt J, Angelin B, Rudling M (2020) Of mice and men: murine bile acids explain species differences in the regulation of bile acid and cholesterol metabolism. J Lipid Res 61(4):480\u2013491","journal-title":"J Lipid Res"},{"issue":"1","key":"869_CR23","doi-asserted-by":"publisher","first-page":"23","DOI":"10.1111\/imr.12579","volume":"279","author":"K Schubert","year":"2017","unstructured":"Schubert K, Olde Damink SWM, von Bergen M, Schaap FG (2017) Interactions between bile salts, gut microbiota, and hepatic innate immunity. Immunol Rev 279(1):23\u201335","journal-title":"Immunol Rev"},{"issue":"11","key":"869_CR24","doi-asserted-by":"publisher","first-page":"9435","DOI":"10.1074\/jbc.M209706200","volume":"278","author":"Y Kawamata","year":"2003","unstructured":"Kawamata Y, Fujii R, Hosoya M, Harada M, Yoshida H, Miwa M, Fukusumi S, Habata Y, Itoh T, Shintani Y, Hinuma S, Fujisawa Y, Fujino M (2003) A G protein-coupled receptor responsive to bile acids. J Biol Chem 278(11):9435\u20139440","journal-title":"J Biol Chem"},{"issue":"7790","key":"869_CR25","doi-asserted-by":"publisher","first-page":"410","DOI":"10.1038\/s41586-019-1865-0","volume":"577","author":"X Song","year":"2020","unstructured":"Song X, Sun X, Oh SF, Wu M, Zhang Y, Zheng W, Geva-Zatorsky N, Jupp R, Mathis D, Benoist C, Kasper DL (2020) Microbial bile acid metabolites modulate gut RORgamma(+) regulatory T cell homeostasis. Nature 577(7790):410\u2013415","journal-title":"Nature"},{"issue":"7785","key":"869_CR26","doi-asserted-by":"publisher","first-page":"143","DOI":"10.1038\/s41586-019-1785-z","volume":"576","author":"S Hang","year":"2019","unstructured":"Hang S, Paik D, Yao L, Kim E, Trinath J, Lu J, Ha S, Nelson BN, Kelly SP, Wu L, Zheng Y, Longman RS, Rastinejad F, Devlin AS, Krout MR, Fischbach MA, Littman DR, Huh JR (2019) Bile acid metabolites control TH17 and Treg cell differentiation. Nature 576(7785):143\u2013148","journal-title":"Nature"},{"issue":"7809","key":"869_CR27","doi-asserted-by":"publisher","first-page":"475","DOI":"10.1038\/s41586-020-2193-0","volume":"581","author":"C Campbell","year":"2020","unstructured":"Campbell C, McKenney PT, Konstantinovsky D, Isaeva OI, Schizas M, Verter J, Mai C, Jin WB, Guo CJ, Violante S, Ramos RJ, Cross JR, Kadaveru K, Hambor J, Rudensky AY (2020) Bacterial metabolism of bile acids promotes generation of peripheral regulatory T cells. Nature 581(7809):475\u2013479","journal-title":"Nature"},{"issue":"10","key":"869_CR28","doi-asserted-by":"publisher","first-page":"1955","DOI":"10.1194\/jlr.R900010-JLR200","volume":"50","author":"JY Chiang","year":"2009","unstructured":"Chiang JY (2009) Bile acids: regulation of synthesis. J Lipid Res 50(10):1955\u20131966","journal-title":"J Lipid Res"},{"issue":"Suppl","key":"869_CR29","doi-asserted-by":"publisher","first-page":"S120","DOI":"10.1194\/jlr.R800026-JLR200","volume":"50","author":"DW Russell","year":"2009","unstructured":"Russell DW (2009) Fifty years of advances in bile acid synthesis and metabolism. J Lipid Res 50(Suppl):S120\u2013S125","journal-title":"J Lipid Res"},{"issue":"10","key":"869_CR30","doi-asserted-by":"publisher","first-page":"1323","DOI":"10.1002\/jat.3644","volume":"38","author":"R Thakare","year":"2018","unstructured":"Thakare R, Alamoudi JA, Gautam N, Rodrigues AD, Alnouti Y (2018) Species differences in bile acids I. Plasma and urine bile acid composition. J Appl Toxicol 38(10):1323\u20131335","journal-title":"J Appl Toxicol"},{"issue":"2","key":"869_CR31","doi-asserted-by":"publisher","first-page":"683","DOI":"10.1152\/physrev.00049.2019","volume":"101","author":"A Perino","year":"2021","unstructured":"Perino A, Demagny H, Velazquez-Villegas L, Schoonjans K (2021) Molecular physiology of bile acid signaling in health, disease, and aging. Physiol Rev 101(2):683\u2013731","journal-title":"Physiol Rev"},{"issue":"11","key":"869_CR32","doi-asserted-by":"publisher","first-page":"609","DOI":"10.1002\/bms.1200141106","volume":"14","author":"F Stellaard","year":"1987","unstructured":"Stellaard F, Sackmann M, Berr F, Paumgartner G (1987) Simultaneous determination of pool sizes and fractional turnover rates, of deoxycholic acid, cholic acid and chenodeoxycholic acid in man by isotope dilution with 2H and 13C labels and serum sampling. Biomed Environ Mass Spectrom 14(11):609\u2013611","journal-title":"Biomed Environ Mass Spectrom"},{"issue":"2","key":"869_CR33","doi-asserted-by":"publisher","first-page":"143","DOI":"10.1016\/0009-8981(88)90004-6","volume":"175","author":"BJ Koopman","year":"1988","unstructured":"Koopman BJ, Kuipers F, Bijleveld CM, van der Molen JC, Nagel GT, Vonk RJ, Wolthers BG (1988) Determination of cholic acid and chenodeoxycholic acid pool sizes and fractional turnover rates by means of stable isotope dilution technique, making use of deuterated cholic acid and chenodeoxycholic acid. Clin Chim Acta 175(2):143\u2013155","journal-title":"Clin Chim Acta"},{"issue":"3","key":"869_CR34","doi-asserted-by":"publisher","first-page":"445","DOI":"10.1016\/j.cmet.2020.02.006","volume":"31","author":"F Kuipers","year":"2020","unstructured":"Kuipers F, de Boer JF, Staels B (2020) Microbiome modulation of the host adaptive immunity through bile acid modification. Cell Metab 31(3):445\u2013447","journal-title":"Cell Metab"},{"key":"869_CR35","doi-asserted-by":"publisher","first-page":"147","DOI":"10.1038\/s41586-021-03421-6","volume":"593","author":"ML Chen","year":"2021","unstructured":"Chen ML, Huang X, Wang H, Hegner C, Liu Y, Shang J, Eliason A, Diao H, Park H, Frey B, Wang G, Mosure SA, Solt LA, Kojetin DJ, Rodriguez-Palacios A, Schady DA, Weaver CT, Pipkin ME, Moore DD, Sundrud MS (2021) CAR directs T cell adaptation to bile acids in the small intestine. Nature 593:147\u2013151","journal-title":"Nature"},{"issue":"4","key":"869_CR36","doi-asserted-by":"publisher","first-page":"783","DOI":"10.1016\/j.jhep.2019.05.030","volume":"71","author":"F Glaser","year":"2019","unstructured":"Glaser F, John C, Engel B, Hoh B, Weidemann S, Dieckhoff J, Stein S, Becker N, Casar C, Schuran FA, Wieschendorf B, Preti M, Jessen F, Franke A, Carambia A, Lohse AW, Ittrich H, Herkel J, Heeren J, Schramm C, Schwinge D (2019) Liver infiltrating T cells regulate bile acid metabolism in experimental cholangitis. J Hepatol 71(4):783\u2013792","journal-title":"J Hepatol"},{"issue":"6","key":"869_CR37","doi-asserted-by":"publisher","first-page":"1370","DOI":"10.1016\/S0016-5085(99)70287-8","volume":"117","author":"PL Jansen","year":"1999","unstructured":"Jansen PL, Strautnieks SS, Jacquemin E, Hadchouel M, Sokal EM, Hooiveld GJ, Koning JH, De Jager-Krikken A, Kuipers F, Stellaard F, Bijleveld CM, Gouw A, Van Goor H, Thompson RJ, Muller M (1999) Hepatocanalicular bile salt export pump deficiency in patients with progressive familial intrahepatic cholestasis. Gastroenterology 117(6):1370\u20131379","journal-title":"Gastroenterology"},{"issue":"8","key":"869_CR38","doi-asserted-by":"publisher","first-page":"423","DOI":"10.4254\/wjh.v12.i8.423","volume":"12","author":"RT Yokoda","year":"2020","unstructured":"Yokoda RT, Rodriguez EA (2020) Review: Pathogenesis of cholestatic liver diseases. World J Hepatol 12(8):423\u2013435","journal-title":"World J Hepatol"},{"key":"869_CR39","doi-asserted-by":"publisher","first-page":"107328","DOI":"10.1016\/j.intimp.2020.107328","volume":"92","author":"M Zou","year":"2021","unstructured":"Zou M, Wang A, Wei J, Cai H, Yu Z, Zhang L, Wang X (2021) An insight into the mechanism and molecular basis of dysfunctional immune response involved in cholestasis. Int Immunopharmacol 92:107328","journal-title":"Int Immunopharmacol"},{"issue":"5","key":"869_CR40","first-page":"269","volume":"16","author":"JM Banales","year":"2019","unstructured":"Banales JM, Huebert RC, Karlsen T, Strazzabosco M, LaRusso NF, Gores GJ (2019) Cholangiocyte pathobiology, Nature reviews. Gastroenterol Hepatol 16(5):269\u2013281","journal-title":"Gastroenterol Hepatol"},{"issue":"3","key":"869_CR41","doi-asserted-by":"publisher","first-page":"244","DOI":"10.1038\/nri1784","volume":"6","author":"DH Adams","year":"2006","unstructured":"Adams DH, Eksteen B (2006) Aberrant homing of mucosal T cells and extra-intestinal manifestations of inflammatory bowel disease. Nat Rev Immunol 6(3):244\u2013251","journal-title":"Nat Rev Immunol"},{"issue":"2","key":"869_CR42","doi-asserted-by":"publisher","first-page":"93","DOI":"10.1038\/s41575-019-0226-7","volume":"17","author":"AF Gulamhusein","year":"2020","unstructured":"Gulamhusein AF, Hirschfield GM (2020) Primary biliary cholangitis: pathogenesis and therapeutic opportunities. Nat Rev Gastroenterol Hepatol 17(2):93\u2013110","journal-title":"Nat Rev Gastroenterol Hepatol"},{"issue":"3","key":"869_CR43","doi-asserted-by":"publisher","first-page":"195","DOI":"10.1016\/S0009-9120(01)00215-6","volume":"34","author":"RG Cameron","year":"2001","unstructured":"Cameron RG, Blendis LM, Neuman MG (2001) Accumulation of macrophages in primary sclerosing cholangitis. Clin Biochem 34(3):195\u2013201","journal-title":"Clin Biochem"},{"issue":"5","key":"869_CR44","doi-asserted-by":"publisher","first-page":"1216","DOI":"10.1002\/hep.1840120523","volume":"12","author":"DL Schmucker","year":"1990","unstructured":"Schmucker DL, Ohta M, Kanai S, Sato Y, Kitani K (1990) Hepatic injury induced by bile salts: correlation between biochemical and morphological events. Hepatology 12(5):1216\u20131221","journal-title":"Hepatology"},{"issue":"9","key":"869_CR45","doi-asserted-by":"publisher","first-page":"e2390","DOI":"10.1038\/cddis.2016.280","volume":"7","author":"MB Afonso","year":"2016","unstructured":"Afonso MB, Rodrigues PM, Simao AL, Ofengeim D, Carvalho T, Amaral JD, Gaspar MM, Cortez-Pinto H, Castro RE, Yuan J, Rodrigues CM (2016) Activation of necroptosis in human and experimental cholestasis. Cell Death Dis 7(9):e2390","journal-title":"Cell Death Dis"},{"key":"869_CR46","doi-asserted-by":"publisher","first-page":"357","DOI":"10.2119\/molmed.2013.00099","volume":"19","author":"R Chen","year":"2013","unstructured":"Chen R, Hou W, Zhang Q, Kang R, Fan XG, Tang D (2013) Emerging role of high-mobility group box 1 (HMGB1) in liver diseases. Mol Med 19:357\u2013366","journal-title":"Mol Med"},{"issue":"4 Pt 1","key":"869_CR47","doi-asserted-by":"publisher","first-page":"1371","DOI":"10.1016\/0016-5085(92)90778-W","volume":"102","author":"Y Calmus","year":"1992","unstructured":"Calmus Y, Arvieux C, Gane P, Boucher E, Nordlinger B, Rouger P, Poupon R (1992) Cholestasis induces major histocompatibility complex class I expression in hepatocytes. Gastroenterology 102(4 Pt 1):1371\u20131377","journal-title":"Gastroenterology"},{"issue":"1","key":"869_CR48","doi-asserted-by":"publisher","first-page":"175","DOI":"10.1016\/j.ajpath.2010.11.026","volume":"178","author":"K Allen","year":"2011","unstructured":"Allen K, Jaeschke H, Copple BL (2011) Bile acids induce inflammatory genes in hepatocytes: a novel mechanism of inflammation during obstructive cholestasis. Am J Pathol 178(1):175\u2013186","journal-title":"Am J Pathol"},{"issue":"4","key":"869_CR49","doi-asserted-by":"publisher","first-page":"998","DOI":"10.1002\/hep.1840400431","volume":"40","author":"JS Gujral","year":"2004","unstructured":"Gujral JS, Liu J, Farhood A, Jaeschke H (2004) Reduced oncotic necrosis in Fas receptor-deficient C57BL\/6J-lpr mice after bile duct ligation. Hepatology 40(4):998\u20131007","journal-title":"Hepatology"},{"issue":"6","key":"869_CR50","doi-asserted-by":"publisher","first-page":"877","DOI":"10.1016\/S0168-8278(96)80292-3","volume":"25","author":"F Polzien","year":"1996","unstructured":"Polzien F, Ramadori G (1996) Increased intercellular adhesion molecule-1 serum concentration in cholestasis. J Hepatol 25(6):877\u2013886","journal-title":"J Hepatol"},{"issue":"4","key":"869_CR51","doi-asserted-by":"publisher","first-page":"1192","DOI":"10.1016\/0016-5085(95)90219-8","volume":"108","author":"P Podevin","year":"1995","unstructured":"Podevin P, Calmus Y, Bonnefis MT, Veyrunes C, Chereau C, Poupon R (1995) Effect of cholestasis and bile acids on interferon-induced 2',5'-adenylate synthetase and NK cell activities. Gastroenterology 108(4):1192\u20131198","journal-title":"Gastroenterology"},{"issue":"6","key":"869_CR52","doi-asserted-by":"publisher","first-page":"1300","DOI":"10.1016\/j.jhep.2017.02.026","volume":"66","author":"F Tacke","year":"2017","unstructured":"Tacke F (2017) Targeting hepatic macrophages to treat liver diseases. J Hepatol 66(6):1300\u20131312","journal-title":"J Hepatol"},{"issue":"1","key":"869_CR53","doi-asserted-by":"publisher","first-page":"102","DOI":"10.1016\/j.jhep.2004.09.019","volume":"42","author":"E Sturm","year":"2005","unstructured":"Sturm E, Havinga R, Baller JF, Wolters H, van Rooijen N, Kamps JA, Verkade HJ, Karpen SJ, Kuipers F (2005) Kupffer cell depletion with liposomal clodronate prevents suppression of Ntcp expression in endotoxin-treated rats. J Hepatol 42(1):102\u2013109","journal-title":"J Hepatol"},{"issue":"2","key":"869_CR54","doi-asserted-by":"publisher","first-page":"357","DOI":"10.1016\/j.jhep.2019.04.001","volume":"71","author":"MH Harms","year":"2019","unstructured":"Harms MH, van Buuren HR, Corpechot C, Thorburn D, Janssen HLA, Lindor KD, Hirschfield GM, Pares A, Floreani A, Mayo MJ, Invernizzi P, Battezzati PM, Nevens F, Ponsioen CY, Mason AL, Kowdley KV, Lammers WJ, Hansen BE, van der Meer AJ (2019) Ursodeoxycholic acid therapy and liver transplant-free survival in patients with primary biliary cholangitis. J Hepatol 71(2):357\u2013365","journal-title":"J Hepatol"},{"issue":"3","key":"869_CR55","doi-asserted-by":"publisher","first-page":"715","DOI":"10.1053\/j.gastro.2005.12.029","volume":"130","author":"A Pares","year":"2006","unstructured":"Pares A, Caballeria L, Rodes J (2006) Excellent long-term survival in patients with primary biliary cirrhosis and biochemical response to ursodeoxycholic Acid. Gastroenterology 130(3):715\u2013720","journal-title":"Gastroenterology"},{"issue":"6","key":"869_CR56","doi-asserted-by":"publisher","first-page":"588","DOI":"10.1007\/s00535-020-01681-z","volume":"55","author":"M Vesterhus","year":"2020","unstructured":"Vesterhus M, Karlsen TH (2020) Emerging therapies in primary sclerosing cholangitis: pathophysiological basis and clinical opportunities. J Gastroenterol 55(6):588\u2013614","journal-title":"J Gastroenterol"},{"issue":"3","key":"869_CR57","doi-asserted-by":"publisher","first-page":"808","DOI":"10.1002\/hep.23082","volume":"50","author":"KD Lindor","year":"2009","unstructured":"Lindor KD, Kowdley KV, Luketic VA, Harrison ME, McCashland T, Befeler AS, Harnois D, Jorgensen R, Petz J, Keach J, Mooney J, Sargeant C, Braaten J, Bernard T, King D, Miceli E, Schmoll J, Hoskin T, Thapa P, Enders F (2009) High-dose ursodeoxycholic acid for the treatment of primary sclerosing cholangitis. Hepatology 50(3):808\u2013814","journal-title":"Hepatology"},{"issue":"4","key":"869_CR58","doi-asserted-by":"publisher","first-page":"603","DOI":"10.1002\/hep.1840150409","volume":"15","author":"U Beuers","year":"1992","unstructured":"Beuers U, Spengler U, Zwiebel FM, Pauletzki J, Fischer S, Paumgartner G (1992) Effect of ursodeoxycholic acid on the kinetics of the major hydrophobic bile acids in health and in chronic cholestatic liver disease. Hepatology 15(4):603\u2013608","journal-title":"Hepatology"},{"issue":"4","key":"869_CR59","doi-asserted-by":"publisher","first-page":"1489","DOI":"10.1002\/hep.23810","volume":"52","author":"U Beuers","year":"2010","unstructured":"Beuers U, Hohenester S, de Buy Wenniger LJ, Kremer AE, Jansen PL, Elferink RP (2010) The biliary HCO(3)(-) umbrella: a unifying hypothesis on pathogenetic and therapeutic aspects of fibrosing cholangiopathies. Hepatology 52(4):1489\u20131496","journal-title":"Hepatology"},{"issue":"3","key":"869_CR60","first-page":"540","volume":"13","author":"D Gurantz","year":"1991","unstructured":"Gurantz D, Schteingart CD, Hagey LR, Steinbach JH, Grotmol T, Hofmann AF (1991) Hypercholeresis induced by unconjugated bile acid infusion correlates with recovery in bile of unconjugated bile acids. Hepatology 13(3):540\u2013550","journal-title":"Hepatology"},{"issue":"5790","key":"869_CR61","doi-asserted-by":"publisher","first-page":"1137","DOI":"10.1126\/science.1128294","volume":"313","author":"U Ozcan","year":"2006","unstructured":"Ozcan U, Yilmaz E, Ozcan L, Furuhashi M, Vaillancourt E, Smith RO, Gorgun CZ, Hotamisligil GS (2006) Chemical chaperones reduce ER stress and restore glucose homeostasis in a mouse model of type 2 diabetes. Science 313(5790):1137\u20131140","journal-title":"Science"},{"issue":"9","key":"869_CR62","first-page":"1194","volume":"86","author":"S Terasaki","year":"1991","unstructured":"Terasaki S, Nakanuma Y, Ogino H, Unoura M, Kobayashi K (1991) Hepatocellular and biliary expression of HLA antigens in primary biliary cirrhosis before and after ursodeoxycholic acid therapy. Am J Gastroenterol 86(9):1194\u20131199","journal-title":"Am J Gastroenterol"},{"issue":"Suppl 1","key":"869_CR63","doi-asserted-by":"publisher","first-page":"S3","DOI":"10.1016\/S2210-7401(12)70015-3","volume":"36","author":"R Poupon","year":"2012","unstructured":"Poupon R (2012) Ursodeoxycholic acid and bile-acid mimetics as therapeutic agents for cholestatic liver diseases: an overview of their mechanisms of action. Clin Res Hepatol Gastroenterol 36(Suppl 1):S3\u2013S12","journal-title":"Clin Res Hepatol Gastroenterol"},{"issue":"7","key":"869_CR64","doi-asserted-by":"publisher","first-page":"1487","DOI":"10.1007\/BF02088577","volume":"41","author":"Y Nishigaki","year":"1996","unstructured":"Nishigaki Y, Ohnishi H, Moriwaki H, Muto Y (1996) Ursodeoxycholic acid corrects defective natural killer activity by inhibiting prostaglandin E2 production in primary biliary cirrhosis. Dig Dis Sci 41(7):1487\u20131493","journal-title":"Dig Dis Sci"},{"issue":"2","key":"869_CR65","doi-asserted-by":"publisher","first-page":"409","DOI":"10.1016\/j.ajpath.2014.10.009","volume":"185","author":"L Verbeke","year":"2015","unstructured":"Verbeke L, Farre R, Verbinnen B, Covens K, Vanuytsel T, Verhaegen J, Komuta M, Roskams T, Chatterjee S, Annaert P, Vander Elst I, Windmolders P, Trebicka J, Nevens F, Laleman W (2015) The FXR agonist obeticholic acid prevents gut barrier dysfunction and bacterial translocation in cholestatic rats. Am J Pathol 185(2):409\u2013419","journal-title":"Am J Pathol"},{"issue":"4","key":"869_CR66","doi-asserted-by":"publisher","first-page":"751","DOI":"10.1053\/j.gastro.2014.12.005","volume":"148","author":"GM Hirschfield","year":"2015","unstructured":"Hirschfield GM, Mason A, Luketic V, Lindor K, Gordon SC, Mayo M, Kowdley KV, Vincent C, Bodhenheimer HC Jr, Pares A, Trauner M, Marschall HU, Adorini L, Sciacca C, Beecher-Jones T, Castelloe E, Bohm O, Shapiro D (2015) Efficacy of obeticholic acid in patients with primary biliary cirrhosis and inadequate response to ursodeoxycholic acid. Gastroenterology 148(4):751\u201361.e8","journal-title":"Gastroenterology"},{"key":"869_CR67","doi-asserted-by":"crossref","unstructured":"Kowdley KV, Luketic V, Chapman R, Hirschfield GM, Poupon R, Schramm C, Vincent C, Rust C, Pares A, Mason A, Marschall HU, Shapiro D, Adorini L, Sciacca C, Beecher-Jones T, Bohm O, Pencek R, Jones D, P.B.C.M.S.G. Obeticholic Acid (2018, 1890-1902) A randomized trial of obeticholic acid monotherapy in patients with primary biliary cholangitis. Hepatology 67(5)","DOI":"10.1002\/hep.29569"},{"issue":"7","key":"869_CR68","doi-asserted-by":"publisher","first-page":"1999","DOI":"10.1053\/j.gastro.2019.11.312","volume":"158","author":"M Eslam","year":"2020","unstructured":"Eslam M, Sanyal AJ, George J, P. International Consensus (2020) MAFLD: A Consensus-Driven Proposed Nomenclature for Metabolic Associated Fatty Liver Disease. Gastroenterology 158(7):1999\u20132014.e1","journal-title":"Gastroenterology"},{"issue":"11","key":"869_CR69","doi-asserted-by":"publisher","first-page":"686","DOI":"10.1038\/nrgastro.2013.171","volume":"10","author":"R Loomba","year":"2013","unstructured":"Loomba R, Sanyal AJ (2013) The global NAFLD epidemic. Nat Rev Gastroenterol Hepatol 10(11):686\u2013690","journal-title":"Nat Rev Gastroenterol Hepatol"},{"issue":"6037","key":"869_CR70","doi-asserted-by":"publisher","first-page":"1519","DOI":"10.1126\/science.1204265","volume":"332","author":"JC Cohen","year":"2011","unstructured":"Cohen JC, Horton JD, Hobbs HH (2011) Human fatty liver disease: old questions and new insights. Science 332(6037):1519\u20131523","journal-title":"Science"},{"issue":"4","key":"869_CR71","doi-asserted-by":"publisher","first-page":"952","DOI":"10.1016\/j.jhep.2011.08.025","volume":"56","author":"LP Bechmann","year":"2012","unstructured":"Bechmann LP, Hannivoort RA, Gerken G, Hotamisligil GS, Trauner M, Canbay A (2012) The interaction of hepatic lipid and glucose metabolism in liver diseases. J Hepatol 56(4):952\u2013964","journal-title":"J Hepatol"},{"issue":"1","key":"869_CR72","doi-asserted-by":"publisher","first-page":"31","DOI":"10.1016\/j.tem.2017.11.002","volume":"29","author":"A Molinaro","year":"2018","unstructured":"Molinaro A, Wahlstrom A, Marschall HU (2018) Role of Bile Acids in Metabolic Control. Trends Endocrinol Metab 29(1):31\u201341","journal-title":"Trends Endocrinol Metab"},{"issue":"2","key":"869_CR73","doi-asserted-by":"publisher","first-page":"383","DOI":"10.1084\/jem.20171965","volume":"215","author":"H Shapiro","year":"2018","unstructured":"Shapiro H, Kolodziejczyk AA, Halstuch D, Elinav E (2018) Bile acids in glucose metabolism in health and disease. J Exp Med 215(2):383\u2013396","journal-title":"J Exp Med"},{"issue":"Suppl 2","key":"869_CR74","doi-asserted-by":"publisher","first-page":"S237","DOI":"10.2337\/dc09-S355","volume":"32","author":"B Staels","year":"2009","unstructured":"Staels B, Fonseca VA (2009) Bile acids and metabolic regulation: mechanisms and clinical responses to bile acid sequestration. Diabetes Care 32(Suppl 2):S237\u2013S245","journal-title":"Diabetes Care"},{"issue":"1","key":"869_CR75","doi-asserted-by":"publisher","first-page":"118","DOI":"10.1002\/hep.25630","volume":"56","author":"N Tanaka","year":"2012","unstructured":"Tanaka N, Matsubara T, Krausz KW, Patterson AD, Gonzalez FJ (2012) Disruption of phospholipid and bile acid homeostasis in mice with nonalcoholic steatohepatitis. Hepatology 56(1):118\u2013129","journal-title":"Hepatology"},{"key":"869_CR76","doi-asserted-by":"publisher","first-page":"114664","DOI":"10.1016\/j.taap.2019.114664","volume":"379","author":"T Suga","year":"2019","unstructured":"Suga T, Yamaguchi H, Ogura J, Shoji S, Maekawa M, Mano N (2019) Altered bile acid composition and disposition in a mouse model of non-alcoholic steatohepatitis. Toxicol Appl Pharmacol 379:114664","journal-title":"Toxicol Appl Pharmacol"},{"issue":"11","key":"869_CR77","doi-asserted-by":"publisher","first-page":"3318","DOI":"10.1007\/s10620-015-3776-8","volume":"60","author":"BC Ferslew","year":"2015","unstructured":"Ferslew BC, Xie G, Johnston CK, Su M, Stewart PW, Jia W, Brouwer KL, Barritt AST (2015) Altered Bile Acid Metabolome in Patients with Nonalcoholic Steatohepatitis. Dig Dis Sci 60(11):3318\u20133328","journal-title":"Dig Dis Sci"},{"issue":"4","key":"869_CR78","doi-asserted-by":"publisher","first-page":"1394","DOI":"10.1002\/hep.26225","volume":"57","author":"LP Bechmann","year":"2013","unstructured":"Bechmann LP, Kocabayoglu P, Sowa JP, Sydor S, Best J, Schlattjan M, Beilfuss A, Schmitt J, Hannivoort RA, Kilicarslan A, Rust C, Berr F, Tschopp O, Gerken G, Friedman SL, Geier A, Canbay A (2013) Free fatty acids repress small heterodimer partner (SHP) activation and adiponectin counteracts bile acid-induced liver injury in superobese patients with nonalcoholic steatohepatitis. Hepatology 57(4):1394\u20131406","journal-title":"Hepatology"},{"issue":"5","key":"869_CR79","doi-asserted-by":"publisher","first-page":"382","DOI":"10.1097\/MEG.0b013e328345c8c7","volume":"23","author":"S Dasarathy","year":"2011","unstructured":"Dasarathy S, Yang Y, McCullough AJ, Marczewski S, Bennett C, Kalhan SC (2011) Elevated hepatic fatty acid oxidation, high plasma fibroblast growth factor 21, and fasting bile acids in nonalcoholic steatohepatitis. Eur J Gastroenterol Hepatol 23(5):382\u2013388","journal-title":"Eur J Gastroenterol Hepatol"},{"issue":"3","key":"869_CR80","doi-asserted-by":"publisher","first-page":"404","DOI":"10.1016\/j.metabol.2010.03.006","volume":"60","author":"SC Kalhan","year":"2011","unstructured":"Kalhan SC, Guo L, Edmison J, Dasarathy S, McCullough AJ, Hanson RW, Milburn M (2011) Plasma metabolomic profile in nonalcoholic fatty liver disease. Metab Clin Exp 60(3):404\u2013413","journal-title":"Metab Clin Exp"},{"issue":"2","key":"869_CR81","doi-asserted-by":"publisher","first-page":"534","DOI":"10.1002\/hep.29359","volume":"67","author":"P Puri","year":"2018","unstructured":"Puri P, Daita K, Joyce A, Mirshahi F, Santhekadur PK, Cazanave S, Luketic VA, Siddiqui MS, Boyett S, Min HK, Kumar DP, Kohli R, Zhou H, Hylemon PB, Contos MJ, Idowu M, Sanyal AJ (2018) The presence and severity of nonalcoholic steatohepatitis is associated with specific changes in circulating bile acids. Hepatology 67(2):534\u2013548","journal-title":"Hepatology"},{"key":"869_CR82","doi-asserted-by":"publisher","first-page":"154457","DOI":"10.1016\/j.metabol.2020.154457","volume":"116","author":"N Nimer","year":"2021","unstructured":"Nimer N, Choucair I, Wang Z, Nemet I, Li L, Gukasyan J, Weeks TL, Alkhouri N, Zein N, Tang WHW, Fischbach MA, Brown JM, Allayee H, Dasarathy S, Gogonea V, Hazen SL (2021) Bile acids profile, histopathological indices and genetic variants for non-alcoholic fatty liver disease progression. Metab Clin Exp 116:154457","journal-title":"Metab Clin Exp"},{"issue":"6","key":"869_CR83","doi-asserted-by":"publisher","first-page":"519","DOI":"10.1097\/MEG.0b013e3282f4710a","volume":"20","author":"MM Aranha","year":"2008","unstructured":"Aranha MM, Cortez-Pinto H, Costa A, da Silva IB, Camilo ME, de Moura MC, Rodrigues CM (2008) Bile acid levels are increased in the liver of patients with steatohepatitis. Eur J Gastroenterol Hepatol 20(6):519\u2013525","journal-title":"Eur J Gastroenterol Hepatol"},{"issue":"2","key":"869_CR84","doi-asserted-by":"publisher","first-page":"132","DOI":"10.1016\/j.taap.2013.01.022","volume":"268","author":"AD Lake","year":"2013","unstructured":"Lake AD, Novak P, Shipkova P, Aranibar N, Robertson D, Reily MD, Lu Z, Lehman-McKeeman LD, Cherrington NJ (2013) Decreased hepatotoxic bile acid composition and altered synthesis in progressive human nonalcoholic fatty liver disease. Toxicol Appl Pharmacol 268(2):132\u2013140","journal-title":"Toxicol Appl Pharmacol"},{"issue":"5","key":"869_CR85","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0151829","volume":"11","author":"M Mouzaki","year":"2016","unstructured":"Mouzaki M, Wang AY, Bandsma R, Comelli EM, Arendt BM, Zhang L, Fung S, Fischer SE, McGilvray IG, Allard JP (2016) Bile Acids and Dysbiosis in Non-Alcoholic Fatty Liver Disease. PLoS One 11(5):e0151829","journal-title":"PLoS One"},{"issue":"10","key":"869_CR86","doi-asserted-by":"publisher","first-page":"3783","DOI":"10.1210\/jc.2017-01397","volume":"102","author":"V Legry","year":"2017","unstructured":"Legry V, Francque S, Haas JT, Verrijken A, Caron S, Chavez-Talavera O, Vallez E, Vonghia L, Dirinck E, Verhaegen A, Kouach M, Lestavel S, Lefebvre P, Van Gaal L, Tailleux A, Paumelle R, Staels B (2017) Bile Acid Alterations Are Associated With Insulin Resistance, but Not With NASH, in Obese Subjects. J Clin Endocrinol Metab 102(10):3783\u20133794","journal-title":"J Clin Endocrinol Metab"},{"issue":"1","key":"869_CR87","doi-asserted-by":"publisher","first-page":"4982","DOI":"10.1038\/s41467-020-18754-5","volume":"11","author":"G Lee","year":"2020","unstructured":"Lee G, You HJ, Bajaj JS, Joo SK, Yu J, Park S, Kang H, Park JH, Kim JH, Lee DH, Lee S, Kim W, Ko G (2020) Distinct signatures of gut microbiome and metabolites associated with significant fibrosis in non-obese NAFLD. Nat Commun 11(1):4982","journal-title":"Nat Commun"},{"issue":"3","key":"869_CR88","doi-asserted-by":"publisher","first-page":"180","DOI":"10.1097\/MOL.0000000000000504","volume":"29","author":"J Heeren","year":"2018","unstructured":"Heeren J, Scheja L (2018) Brown adipose tissue and lipid metabolism. Curr Opin Lipidol 29(3):180\u2013185","journal-title":"Curr Opin Lipidol"},{"issue":"7","key":"869_CR89","doi-asserted-by":"publisher","first-page":"1270","DOI":"10.1194\/jlr.M093229","volume":"60","author":"T Raselli","year":"2019","unstructured":"Raselli T, Hearn T, Wyss A, Atrott K, Peter A, Frey-Wagner I, Spalinger MR, Maggio EM, Sailer AW, Schmitt J, Schreiner P, Moncsek A, Mertens J, Scharl M, Griffiths WJ, Bueter M, Geier A, Rogler G, Wang Y, Misselwitz B (2019) Elevated oxysterol levels in human and mouse livers reflect nonalcoholic steatohepatitis. J Lipid Res 60(7):1270\u20131283","journal-title":"J Lipid Res"},{"issue":"7","key":"869_CR90","doi-asserted-by":"publisher","first-page":"839","DOI":"10.1038\/nm.4357","volume":"23","author":"A Worthmann","year":"2017","unstructured":"Worthmann A, John C, Ruhlemann MC, Baguhl M, Heinsen FA, Schaltenberg N, Heine M, Schlein C, Evangelakos I, Mineo C, Fischer M, Dandri M, Kremoser C, Scheja L, Franke A, Shaul PW, Heeren J (2017) Cold-induced conversion of cholesterol to bile acids in mice shapes the gut microbiome and promotes adaptive thermogenesis. Nat Med 23(7):839\u2013849","journal-title":"Nat Med"},{"issue":"10","key":"869_CR91","doi-asserted-by":"publisher","first-page":"1881","DOI":"10.1136\/gutjnl-2017-314307","volume":"67","author":"N Jiao","year":"2018","unstructured":"Jiao N, Baker SS, Chapa-Rodriguez A, Liu W, Nugent CA, Tsompana M, Mastrandrea L, Buck MJ, Baker RD, Genco RJ, Zhu R, Zhu L (2018) Suppressed hepatic bile acid signalling despite elevated production of primary and secondary bile acids in NAFLD. Gut 67(10):1881\u20131891","journal-title":"Gut"},{"key":"869_CR92","doi-asserted-by":"crossref","unstructured":"Govaere O, Cockell S, Tiniakos D, Queen R, Younes R, Vacca M, Alexander L, Ravaioli F, Palmer J, Petta S, Boursier J, Rosso C, Johnson K, Wonders K, Day CP, Ekstedt M, Oresic M, Darlay R, Cordell HJ, Marra F, Vidal-Puig A, Bedossa P, Schattenberg JM, Clement K, Allison M, Bugianesi E, Ratziu V, Daly AK, Anstee QM (2020) Transcriptomic profiling across the nonalcoholic fatty liver disease spectrum reveals gene signatures for steatohepatitis and fibrosis. Sci Transl Med 12(572)","DOI":"10.1126\/scitranslmed.aba4448"},{"issue":"10","key":"869_CR93","doi-asserted-by":"publisher","first-page":"1831","DOI":"10.1194\/jlr.M069807","volume":"57","author":"H Liu","year":"2016","unstructured":"Liu H, Pathak P, Boehme S, Chiang JY (2016) Cholesterol 7alpha-hydroxylase protects the liver from inflammation and fibrosis by maintaining cholesterol homeostasis. J Lipid Res 57(10):1831\u20131844","journal-title":"J Lipid Res"},{"issue":"5","key":"869_CR94","doi-asserted-by":"publisher","first-page":"e64721","DOI":"10.1371\/journal.pone.0064721","volume":"8","author":"M Bjursell","year":"2013","unstructured":"Bjursell M, Wedin M, Admyre T, Hermansson M, Bottcher G, Goransson M, Linden D, Bamberg K, Oscarsson J, Bohlooly YM (2013) Ageing Fxr deficient mice develop increased energy expenditure, improved glucose control and liver damage resembling NASH. PLoS One 8(5):e64721","journal-title":"PLoS One"},{"issue":"3","key":"869_CR95","doi-asserted-by":"publisher","first-page":"955","DOI":"10.1002\/hep.30513","volume":"70","author":"JM Ferrell","year":"2019","unstructured":"Ferrell JM, Pathak P, Boehme S, Gilliland T, Chiang JYL (2019) Deficiency of both farnesoid X receptor and Takeda G protein-coupled receptor 5 exacerbated liver fibrosis in mice. Hepatology 70(3):955\u2013970","journal-title":"Hepatology"},{"issue":"4","key":"869_CR96","doi-asserted-by":"publisher","first-page":"1133","DOI":"10.1111\/liv.12456","volume":"35","author":"J Schmitt","year":"2015","unstructured":"Schmitt J, Kong B, Stieger B, Tschopp O, Schultze SM, Rau M, Weber A, Mullhaupt B, Guo GL, Geier A (2015) Protective effects of farnesoid X receptor (FXR) on hepatic lipid accumulation are mediated by hepatic FXR and independent of intestinal FGF15 signal. Liver Int 35(4):1133\u20131144","journal-title":"Liver Int"},{"issue":"4","key":"869_CR97","doi-asserted-by":"publisher","first-page":"1421","DOI":"10.1002\/hep.24525","volume":"54","author":"YD Wang","year":"2011","unstructured":"Wang YD, Chen WD, Yu D, Forman BM, Huang W (2011) The G-protein-coupled bile acid receptor, Gpbar1 (TGR5), negatively regulates hepatic inflammatory response through antagonizing nuclear factor kappa light-chain enhancer of activated B cells (NF-kappaB) in mice. Hepatology 54(4):1421\u20131432","journal-title":"Hepatology"},{"issue":"1","key":"869_CR98","first-page":"55","volume":"11","author":"FG Schaap","year":"2014","unstructured":"Schaap FG, Trauner M, Jansen PL (2014) Bile acid receptors as targets for drug development, Nature reviews. Gastroenterol Hepatol 11(1):55\u201367","journal-title":"Gastroenterol Hepatol"},{"issue":"8","key":"869_CR99","doi-asserted-by":"publisher","first-page":"678","DOI":"10.1038\/nrd2619","volume":"7","author":"C Thomas","year":"2008","unstructured":"Thomas C, Pellicciari R, Pruzanski M, Auwerx J, Schoonjans K (2008) Targeting bile-acid signalling for metabolic diseases. Nat Rev Drug Discov 7(8):678\u2013693","journal-title":"Nat Rev Drug Discov"},{"issue":"9972","key":"869_CR100","doi-asserted-by":"publisher","first-page":"956","DOI":"10.1016\/S0140-6736(14)61933-4","volume":"385","author":"BA Neuschwander-Tetri","year":"2015","unstructured":"Neuschwander-Tetri BA, Loomba R, Sanyal AJ, Lavine JE, Van Natta ML, Abdelmalek MF, Chalasani N, Dasarathy S, Diehl AM, Hameed B, Kowdley KV, McCullough A, Terrault N, Clark JM, Tonascia J, Brunt EM, Kleiner DE, Doo E, Network NCR (2015) Farnesoid X nuclear receptor ligand obeticholic acid for non-cirrhotic, non-alcoholic steatohepatitis (FLINT): a multicentre, randomised, placebo-controlled trial. Lancet 385(9972):956\u2013965","journal-title":"Lancet"},{"issue":"3","key":"869_CR101","doi-asserted-by":"publisher","first-page":"574","DOI":"10.1053\/j.gastro.2013.05.042","volume":"145","author":"S Mudaliar","year":"2013","unstructured":"Mudaliar S, Henry RR, Sanyal AJ, Morrow L, Marschall HU, Kipnes M, Adorini L, Sciacca CI, Clopton P, Castelloe E, Dillon P, Pruzanski M, Shapiro D (2013) Efficacy and safety of the farnesoid X receptor agonist obeticholic acid in patients with type 2 diabetes and nonalcoholic fatty liver disease. Gastroenterology 145(3):574\u201382.e1","journal-title":"Gastroenterology"},{"issue":"10215","key":"869_CR102","doi-asserted-by":"publisher","first-page":"2184","DOI":"10.1016\/S0140-6736(19)33041-7","volume":"394","author":"ZM Younossi","year":"2019","unstructured":"Younossi ZM, Ratziu V, Loomba R, Rinella M, Anstee QM, Goodman Z, Bedossa P, Geier A, Beckebaum S, Newsome PN, Sheridan D, Sheikh MY, Trotter J, Knapple W, Lawitz E, Abdelmalek MF, Kowdley KV, Montano-Loza AJ, Boursier J, Mathurin P, Bugianesi E, Mazzella G, Olveira A, Cortez-Pinto H, Graupera I, Orr D, Gluud LL, Dufour JF, Shapiro D, Campagna J, Zaru L, MacConell L, Shringarpure R, Harrison S, Sanyal AJ, R.S. Investigators (2019) Obeticholic acid for the treatment of non-alcoholic steatohepatitis: interim analysis from a multicentre, randomised, placebo-controlled phase 3 trial. Lancet 394(10215):2184\u20132196","journal-title":"Lancet"},{"key":"869_CR103","doi-asserted-by":"crossref","unstructured":"Li R, Andreu-Sanchez S, Kuipers F, Fu J (2021) Gut microbiome and bile acids in obesity-related diseases, Best practice & research. Clin Endocrinol Metab 101493","DOI":"10.1016\/j.beem.2021.101493"},{"issue":"4","key":"869_CR104","doi-asserted-by":"publisher","first-page":"665","DOI":"10.1136\/gutjnl-2019-318416","volume":"69","author":"T Liwinski","year":"2020","unstructured":"Liwinski T, Zenouzi R, John C, Ehlken H, Ruhlemann MC, Bang C, Groth S, Lieb W, Kantowski M, Andersen N, Schachschal G, Karlsen TH, Hov JR, Rosch T, Lohse AW, Heeren J, Franke A, Schramm C (2020) Alterations of the bile microbiome in primary sclerosing cholangitis. Gut 69(4):665\u2013672","journal-title":"Gut"},{"issue":"3","key":"869_CR105","doi-asserted-by":"publisher","first-page":"549","DOI":"10.1016\/j.jhep.2017.05.009","volume":"67","author":"P Fickert","year":"2017","unstructured":"Fickert P, Hirschfield GM, Denk G, Marschall HU, Altorjay I, Farkkila M, Schramm C, Spengler U, Chapman R, Bergquist A, Schrumpf E, Nevens F, Trivedi P, Reiter FP, Tornai I, Halilbasic E, Greinwald R, Prols M, Manns MP, Trauner M, P.S.C.n.S.G. European (2017) norUrsodeoxycholic acid improves cholestasis in primary sclerosing cholangitis. J Hepatol 67(3):549\u2013558","journal-title":"J Hepatol"}],"container-title":["Seminars in Immunopathology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00281-021-00869-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00281-021-00869-6\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00281-021-00869-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,9,16]],"date-time":"2021-09-16T00:03:45Z","timestamp":1631750625000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00281-021-00869-6"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,7,8]]},"references-count":105,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2021,8]]}},"alternative-id":["869"],"URL":"https:\/\/doi.org\/10.1007\/s00281-021-00869-6","relation":{},"ISSN":["1863-2297","1863-2300"],"issn-type":[{"value":"1863-2297","type":"print"},{"value":"1863-2300","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,7,8]]},"assertion":[{"value":"19 April 2021","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"14 May 2021","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"8 July 2021","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"J.H. has received research grants from the Deutsche Forschungsgemeinschaft (SFB841). All other authors declare no conflict of interest.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}}]}}